NCT06268964View on ClinicalTrials.gov

Exploring Treatments for Children's Abdominal Pain: Comparing Trimebutine and Probiotics

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2025

Conditions
Functional Abdominal Pain SyndromeFunctional Gastrointestinal DisordersIrritable Bowel Syndrome Variant of Childhood
Interventions
DRUG

Trimebutine

Prescription of trimebutine at pediatric dosage (15 mg/kg/day), divided into 2 daily doses, for 8 weeks.

DIETARY_SUPPLEMENT

Lactobacillus rhamnosus

Prescription of Lactobacillus rhamnosus 5 billion CFUs in chewable tablets, a single dose (night) for 8 weeks.

OTHER

Placebo

Prescription of a placebo, 250 mg microcrystalline cellulose tablets, a single dose (night) for 8 weeks.

Trial Locations (1)

28040

RECRUITING

School of Medicine, University of Colima, Colima

All Listed Sponsors
lead

Universidad de Colima

OTHER

NCT06268964 - Exploring Treatments for Children's Abdominal Pain: Comparing Trimebutine and Probiotics | Biotech Hunter | Biotech Hunter